• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Evolution of eConsent Technology Leads to Greater Adoption from Sponsors and Clinical Trials Sites

Evolution of eConsent Technology Leads to Greater Adoption from Sponsors and Clinical Trials Sites

June 11, 2018
Suz Redfearn

eConsent has developed a reputation for being the next big technological innovation in clinical trials, and adoption efforts are accelerating.

Numerous industry surveys have shown that most of the top 50 Pharma companies are engaged or planning an eConsent initiative in the near future, with many of them already having an eConsent strategy in place.

Technology advances have made eConsent implementation much easier. For example, newer SaaS-based applications that leverage integration with the IRB review now can be implemented rapidly, and at a much lower cost.

Sponsors who love their paper-based processes have complained that solutions like eConsent are too expensive, but the cost of adding eConsent to a study is more than recouped through enhanced study start-up time, reduced monitoring visits, and better subject retention.

All the same, many sponsor efforts are still in pilot phase, said Neetu Pundir, who manages product strategy for CRF Health’s electronic consent offering, TrialConsent.

“This industry is very conservative and cautious, and a lot of organizations have wanted to do a pilot before rolling this out,” said Pundir. “But as sponsors of all sizes and types are beginning to finish their pilots now, we’re seeing them go right into adoption.”

Pundir says she’s seeing a paradigm shift as sponsors now move away from using paper processes in one of the last areas where they had clung to paper. Now, she says, there may be a bit more of a delay as sponsors formalize their efforts around eConsent, adding staff familiar with eConsent, or training staff they already have. But for the most part, she said, their resistance to it is gone.

The fact that it took so long for sponsors to accept it hasn’t surprised Susan Vallow, vice president of Electronic Clinical Outcome Assessments (eCOA) Solutions for MedAvante-ProPhase, who has worked in eCOA for 20 years, and watched it take almost that long for sponsors to get comfortable with paperless processes in other realms of clinical research, like clinical report forms.

Sites also are more open to adopting eConsent now, as the technology behind it has gotten more streamlined, and is easier to use, as opposed to just another complicated thing sponsors want sites to come up to speed on.

Plus, the new eConsent solutions also have version control imbedded in them, said Vallow, so sites no longer have to hunt around for the multiple versions of an eConsent document. Instead, all versions are accessible, having been tracked electronically.

So what’s keeping all sponsors from adopting eConsent? Some countries, including China and Germany, don’t allow eSignatures, which are a key part of eConsent. Many other countries have laws around eSignatures that are vague enough to spook sponsors.

With virtual trials — otherwise known as direct-to-patient trials — beginning to enter the marketplace, eConsent will only become more prominent.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing